Roth Capital Upgrades Synta Pharmaceuticals (SNTA) to Buy
Roth Capital upgrades Synta Pharmaceuticals (SNTA) from Hold to Buy. Price target increased from $2 to $4.
To see more analyst ratings on SNTA Click Here.
Synta Pharmaceuticals Corp., a biopharmaceutical company, focuses on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases.
Stocks Mentioned
Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
